Deep Tech Startups

ArcherX develops quantum technologies with applications in computing, sensing, and healthcare.

1 investor

Arcoris bio develops MUSE®, a self-assembling, enzyme-free DNA nanotechnology for signal amplification and multiplex imaging that detects protein, DNA, and RNA biomarkers across assays such as immunofluorescence, immunohistochemistry, and in situ hybridization. It sells ready-to-use immunoMUSE® kits for researchers and offers custom solutions, licensing, and white-label/B2B technology integration to partners.

1 investor

Arcten builds long-horizon autonomous agents for research and coding tasks. The company has roots in AI research at Caltech.

1 investor

ARETEK, formerly Printerra, develops additive (3D printing) technologies for the global construction industry.

1 investor

Argobio is a European venture builder that co-founds, invests in, and operates alongside early-stage biotech companies, turning academic scientific discoveries into VC-ready ventures with validated technology and management. It works across academia, venture capital, and pharma to develop a pipeline of therapeutics spanning multiple indications and modalities in Europe.

1 investor

ARGON provides 3D measurement services and application-specific metrology solutions, including 3D scanning, tactile probing, quality control, and digitizing for parts ranging from 1cm to 100m. It serves industrial clients across various sectors, including those supporting the energy transition, with services, turnkey solutions, and ongoing support and maintenance.

1 investor

Argonaute RNA develops siRNA-based (RNA interference) therapeutics, with a pipeline focused on cardiovascular disease, combining oligonucleotide chemistry and drug development expertise. The UK biotech takes early-stage academic ideas through preclinical and clinical development.

1 investor

ArgusEye develops LSPR-based biosensor systems for real-time monitoring and analytics of bioprocesses in biopharmaceutical development and manufacturing. Its patented Auga platform combines sensor hardware, sensor chips, and software to track critical quality attributes and process parameters, including in-line detection of antibody aggregates and fragments during purification.

1 investor

Aria Sensing develops ultra-wideband (UWB) radar devices capable of high-resolution sensing tasks such as vital signs detection and gesture recognition. The radars are designed to operate reliably across varying conditions, penetrate obstacles, and consume less power than comparable high-resolution radar technologies.

1 investor

Aridge develops flying cars, including the Land Aircraft Carrier (a modular flying vehicle) and the A868, a high-speed, long-range full tilt-rotor flying car. The company also offers flying experience programs across multiple camp scenarios.

1 investor

Arisdyne provides process technologies for industrial applications, working with process engineers and plant managers to improve outcomes in areas such as biodiesel production, wastewater and biogas treatment, and graphene manufacturing. Its solutions aim to reduce catalyst consumption, increase throughput, boost methane production, and produce thin graphene platelets.

1 investor

Aristo develops a context-aware AI memory layer that lets users control their own data, focusing on on-device model optimization and efficient AI systems. It emphasizes performance alongside user privacy and data authority.

1 investor

ARMGO develops a novel class of therapeutics called Rycals that target ryanodine receptors (RyRs) to correct calcium channel dysfunction in serious diseases with high unmet need. Its lead candidate, Surlorian, is being developed for heart failure by addressing an underlying driver of disease progression.

1 investor

Armory Technologies develops origami-inspired composite materials (Origami Composites) that are lighter, stronger, and structurally optimized, with properties driven by geometric structure rather than molecular makeup. Its flagship ArmorONE panels serve applications such as truck body and trailer panels, air mobility crash safety, and geothermal energy systems.

1 investor

ARMR Sciences is developing conjugate vaccines and biologic countermeasures, including its lead candidate ARMR-100, designed to bind fentanyl in the bloodstream and prevent overdose from synthetic drugs. It targets high-risk populations such as first responders, military personnel, and individuals in recovery, working on a platform approach to address emerging drug threats.</parameter> <parameter name="sector_codes">["biotech", "healthtech", "deeptech"]

1 investor

Aronora is a clinical-stage biotech developing antithrombotic therapies, including factor XI/XIa inhibitors and thrombolytic drug candidates, to treat and manage thrombotic and thromboembolic conditions such as acute ischemic stroke, heart attack, and pulmonary embolism. Its pipeline of cardio-hematology programs targets patients requiring time-sensitive thrombolytic intervention or management of thrombosis risk.

1 investor

Arrepath uses machine learning to discover new small-molecule drug classes, treating heterogeneous bioactivity data as a modeling asset to work with small datasets and novel chemistry. Its lead program is an oral small molecule for outpatient urinary tract infections, with a second program targeting non-tuberculous mycobacterial infections, and its platform is built to generalize across therapeutic areas.

1 investor

ArrowBiome develops precision microbiome actives—including phage-derived enzymes and engineered particles—that selectively target bacteria linked to acne and body odour while preserving beneficial skin bacteria. It supplies these clinically validated, patent-protected ingredients to beauty and fragrance companies, from global multinationals to indie brands, through a global distributor network.

1 investor

Arrowsmith Genetics is a preclinical-stage drug discovery company developing therapeutics from genetic research conducted at UBC and BC Cancer. The company was founded to advance potential treatments derived from 20+ years of scientific insights in cancer and genetic biology.

1 investor

Artielle Immunotherapeutics develops DRhQ, a therapeutic platform that targets the CD74 receptor and inhibits macrophage migration inhibitory factor (MIF) to treat neuroinflammatory conditions such as progressive multiple sclerosis and advanced cancers. The company builds on research from OHSU and the VA Portland Healthcare System.

1 investor

Artis BioSolutions develops synthetic DNA and provides integrated manufacturing services for genetic medicine and advanced therapeutic modalities, including cell therapy, gene therapy, mRNA, gene editing, and vaccines. The company serves genetic medicine developers seeking to accelerate clinical development and GMP manufacturing within a single quality framework.

1 investor

Aryballe builds silicon photonics-based olfactory sensors that capture and analyze the "fingerprint" of volatile organic compounds (VOCs) for odor detection and quality control. Its products (NeOse, NeOse Advance, and an embeddable Core Sensor Module) serve industries including healthcare, food and beverage, automotive and manufacturing, and cosmetics.

1 investor

Arycs Technologies develops power-efficient, coherent-class optical connectivity based on silicon photonics, coherent DSP, and integrated optical architectures. Its optical links are aimed at AI, cloud, telecom, and edge infrastructure, targeting high bandwidth per watt within the power constraints of data centers and AI networks.

1 investor

ASAPI builds post-training data systems designed to make AI agent judgment dependable across long, complex projects. The company develops infrastructure aimed at improving agent reliability, planning, and adaptation.

1 investor